Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5-35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.
Safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to <2 years of age with Invasive candidiasis, including candidemia / E., Roilides; F., Carlesse; M., Tawadrous; H., Leister-Tebbe; U., Conte; S., Raber; R., Swanson; J. L., Yan; J. A., Aram; The Anidulafungin A8851008 Pediatric Study Group members are as follows: Natalia Dmitrieva, Queiroz-Telles F.; Arnold, Sandra; Arrieta, Antonio; Motta, Fabio; Chiu, Cheng-Hsun; Gentile, Giuseppe; Joo Lyu, Chuhl; Patrick Lee, Brian; Syriopoulou, Vassiliki; Deveikis, Audra; Deville, Jaime; Jin Seo, Jong; Shipitsina, Irina; Horigoshi, Nelson; Robinson, Joan; Grundy, Richard; Steinbach, William; Gedeit, Rainer. - In: THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. - ISSN 0891-3668. - 39:4(2020), pp. 305-309. [10.1097/INF.0000000000002568]
Safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to <2 years of age with Invasive candidiasis, including candidemia
Giuseppe GentileMembro del Collaboration Group
;
2020
Abstract
Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5-35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
Roilides_Safety_2020 .pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
328.86 kB
Formato
Adobe PDF
|
328.86 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
